INTERNATIONAL PATENT: TAKEDA PHARMACEUTICAL COMPANY LIMITED FILES APPLICATION FOR "ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY"

GENEVA, March 23 -- TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1, Doshomachi 4-chome, Chuo-kuOsaka, 540-8645) filed a patent application (PCT/IB2025/000498) for "ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY" on Sep 12, 2025. With publication no. WO/2026/058045, the details related to the patent application was published on Mar 19, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): YAJNIK, Vijay (c/o Takeda Pharmaceuticals USA, Inc.500 Kendall StreetCambridge, MA 02142)

Abstract: Provided herein are combination therapies comprising an alpha4beta7 inhibitor, e.g., an anti-alpha4be...